Gordian Bio entered a collaboration with Pfizer to deploy Gordian’s in vivo mosaic screening platform in visceral adipose tissue to discover and prioritize obesity targets directly in disease‑relevant tissue. The partnership will screen hundreds of gene targets in situ using pooled AAV libraries, tissue‑specific promoters and single‑cell sequencing readouts. Gordian argues the approach overcomes limitations of ex vivo models by capturing multicellular interactions and physiologic context in visceral fat depots that drive metabolic disease. Pfizer gains access to large-scale causal functional genomics data to inform target nomination for obesity and cardiometabolic programs. The deal highlights a platform‑first partnership model: pharma buys large, in‑tissue functional datasets rather than single-target projects, accelerating target de‑risking for complex systemic diseases.